Table 1 Gain of a major response by switching between different available biological agents in rheumatoid arthritis
Results | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Study | Number of patients | Switch type | ACR20 | ACR50 | ACR70 | DAS44 <1.6 or DAS28 <2.6 | ΔDAS P< 0.05 | Evidence levela | Strengtha |
Anti-TNFα blockers | |||||||||
[3] | 25 | IFX → ETA | 64% | 23% | 5% | - | - | 3b | B |
[4] | 95 | IFX → ETA | 38% | 24% | 15% | - | 6.46 → 4.97 | 3b | B |
[5] | 28 | ETA → IFX | 62% | 30.7% | - | 15.4% | 5.2 → 4 | 3b | B |
[6] | 6,610 | ETA/IFX → ADA | 60% | 33% | 13% | 12% | 31% (-1.9 ± 1.4) | 2b | B |
[7] | 25 | IFX → ADA | 75% | 50% | 33% | - | 5.6 → 3.2 | 3b | B |
Anti-CD20 | |||||||||
[8] | 311 | Anti-TNFα → RTX | 51% | 27% | 12% | 9% | 15% (ΔDAS > 1.2) | 1b | A |
SR CTLA-4 | |||||||||
[10] | 391 | Anti-TNFα → ABA | 50.4% | 20.3% | 10.2% | 10.0% | - | 1b | A |
[11] | 1,046 | Anti-TNFα → ABA | - | - | - | 13.0% | 56.1% (-2.0) | 1b | A |
Interleukin-6R inhibitor | |||||||||
[12] | 499 | Anti-TNFα → TOC | 50.0% | 28.8% | 12.4% | 30.1% | - | 1b | A |